Knowledge HQ

All
Publications

Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy

Evaluated TIL ACT for ovarian cancer. TILs were expanded using a 'TIL 3.0' method combining IL-2 with agonistic 4-1BB and anti-CD3 antibodies in G-Rex 10. This method significantly increased CD8+ TIL yield and success rates compared to IL-2 alone, producing tumor-reactive T cells in 2-3 weeks.
Download Now
Publications

Identification of protective T-cell antigens for smallpox vaccines

Study identifying E3L as a key antigen for protective T-cell immunity against vaccinia virus. Virus-specific T cells (VSTs) were generated, referencing previous protocols using G-Rex cultureware.
Download Now
Publications

Electroporation of NKG2D RNA CAR Improves Vg9Vd2 T Cell Responses against Human Solid Tumor Xenografts

Study improving Vg9Vd2 T cell responses using NKG2D RNA CARs. Cells were expanded using K562 aAPCs in G-Rex vessels before electroporation. CAR-modified cells showed enhanced cytotoxicity against solid tumors in vitro and in vivo.
Download Now
Publications

“Mini” bank of only 8 donors supplies CMV-directed T cells to diverse recipients

Production of a third-party CMV-specific T cell (CMVST) bank. Cells were expanded using G-Rex 5 and G-Rex 100M. The bank successfully provided matched lines for 96.6% of screened patients with 100% response rate in treated patients.
Download Now
Publications

Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells

Development of 'NKF' feeder cells (OCI-AML3 with mbIL-21) for NK expansion. The system allows large-scale expansion (>10,000 fold) and was validated in G-Rex. Expanded NK cells showed high cytotoxicity and metabolic activation.
Download Now
Publications

NK-92 cellular therapy for pediatric relapsed/refractory Ewing sarcoma

Case report of a pediatric patient with relapsed Ewing sarcoma treated with intratumoral injections of NK-92 cells. NK-92 cells were expanded in GMP conditions using the G-Rex culture system. Local tumor regression was observed.
Download Now
Publications

Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients

Clinical trial of mRNA-engineered NKG2D CAR-NK cells in metastatic colorectal cancer. NK cells were expanded from PBMCs using K562 feeder cells in G-Rex 100 vessels. Treatment was safe and showed tumor regression in local injection sites.
Download Now
Publications

Extracellular vesicles derived from natural killer cells use multiple cytotoxic proteins and killing mechanisms to target cancer cells

Study on extracellular vesicles (EVs) derived from NK cells. NK cells were propagated and activated using K562-mbIL21 aAPCs in G-Rex culture devices. NK-EVs contained cytotoxic proteins and induced cell death in cancer cells via multiple mechanisms.
Download Now
Publications

Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors

Demonstrated multiplex base editing (PDCD1, TRAC, B2M) in T cells to create allogeneic CAR-T cells. Edited cells were expanded in G-Rex vessels. The method reduced double-strand breaks and translocations compared to Cas9 nuclease.
Download Now
Publications

Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality

Study on gene editing T cells to place CAR and IL-12P70 under endogenous control (TRAC, IL2Ra, PDCD1). TRACCAR T cells were expanded in G-Rex 10 devices. The engineered cells showed regulated cytokine secretion and improved anti-tumor activity.
Download Now
Publications

PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY

Patent describing the Gen 2 manufacturing process for TILs. Detailed methods include the use of G-Rex 100M and G-Rex 500M for the Rapid Expansion Protocol (REP) to shorten culture time and improve efficiency compared to the Gen 1 process.
Download Now
Publications

Lifileucel, a Potential Therapy for Metastatic Melanoma Patients who are Primary Refractory to Prior Anti-PD-1 Therapy

Clinical data on Lifileucel (LN-144) for metastatic melanoma. The manufacturing process involves a 22-day protocol using G-Rex. Shows 40.5% ORR in primary refractory patients.
Download Now

ScaleReady is a joint venture between Wilson Wolf Manufacturing and Bio-Techne.